134 related articles for article (PubMed ID: 21458239)
1. Characteristics and predictors of long-term institutionalization in patients with schizophrenia.
Uggerby P; Nielsen RE; Correll CU; Nielsen J
Schizophr Res; 2011 Sep; 131(1-3):120-6. PubMed ID: 21458239
[TBL] [Abstract][Full Text] [Related]
2. Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: A nation-wide pharmacoepidemiological study.
Sneider B; Pristed SG; Correll CU; Nielsen J
Eur Neuropsychopharmacol; 2015 Oct; 25(10):1669-76. PubMed ID: 26256007
[TBL] [Abstract][Full Text] [Related]
3. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
[TBL] [Abstract][Full Text] [Related]
4. Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study.
Nielsen J; Nielsen RE; Correll CU
J Clin Psychopharmacol; 2012 Oct; 32(5):678-83. PubMed ID: 22926603
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations.
Velligan DI; Carroll C; Lage MJ; Fairman K
Psychiatr Serv; 2015 Feb; 66(2):127-33. PubMed ID: 25321616
[TBL] [Abstract][Full Text] [Related]
6. Trends in and Predictors of Long-Term Antipsychotic Polypharmacy Use Among Ohio Medicaid Patients with Schizophrenia, 2008-2014.
Fontanella CA; Hiance-Steelesmith DL; Guirgis H; Campo JV
Psychiatr Serv; 2018 Sep; 69(9):1015-1020. PubMed ID: 29962308
[TBL] [Abstract][Full Text] [Related]
7. Geographical and temporal variations in clozapine prescription for schizophrenia.
Nielsen J; Røge R; Schjerning O; Sørensen HJ; Taylor D
Eur Neuropsychopharmacol; 2012 Nov; 22(11):818-24. PubMed ID: 22503785
[TBL] [Abstract][Full Text] [Related]
8. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study.
Baandrup L; Gasse C; Jensen VD; Glenthoj BY; Nordentoft M; Lublin H; Fink-Jensen A; Lindhardt A; Mortensen PB
J Clin Psychiatry; 2010 Feb; 71(2):103-8. PubMed ID: 19895781
[TBL] [Abstract][Full Text] [Related]
9. Clozapine protects bone mineral density in female patients with schizophrenia.
Lin CH; Huang KH; Chang YC; Huang YC; Hsu WC; Lin CY; Huang-Chih Chou F; Tsai GE; Lane HY
Int J Neuropsychopharmacol; 2012 Aug; 15(7):897-906. PubMed ID: 22014454
[TBL] [Abstract][Full Text] [Related]
10. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach.
Lund BC; Perry PJ; Brooks JM; Arndt S
Arch Gen Psychiatry; 2001 Dec; 58(12):1172-6. PubMed ID: 11735847
[TBL] [Abstract][Full Text] [Related]
11. Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study.
Wimberley T; Støvring H; Sørensen HJ; Horsdal HT; MacCabe JH; Gasse C
Lancet Psychiatry; 2016 Apr; 3(4):358-66. PubMed ID: 26922475
[TBL] [Abstract][Full Text] [Related]
12. Risk of New-Onset Diabetes After Long-Term Treatment With Clozapine in Comparison to Other Antipsychotics in Patients With Schizophrenia.
Schulte PF; Bocxe JT; Doodeman HJ; van Haelst IM; Cohen D
J Clin Psychopharmacol; 2016 Apr; 36(2):115-9. PubMed ID: 26872114
[TBL] [Abstract][Full Text] [Related]
13. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand.
Wheeler AJ
Ann Pharmacother; 2008 Jun; 42(6):852-60. PubMed ID: 18477732
[TBL] [Abstract][Full Text] [Related]
14. Predictors of clozapine discontinuation in patients with schizophrenia.
Krivoy A; Malka L; Fischel T; Weizman A; Valevski A
Int Clin Psychopharmacol; 2011 Nov; 26(6):311-5. PubMed ID: 21849905
[TBL] [Abstract][Full Text] [Related]
15. Schizophrenia, antipsychotics and risk of hip fracture: a population-based analysis.
Sørensen HJ; Jensen SO; Nielsen J
Eur Neuropsychopharmacol; 2013 Aug; 23(8):872-8. PubMed ID: 23642346
[TBL] [Abstract][Full Text] [Related]
16. Real-world effectiveness of clozapine in patients with bipolar disorder: results from a 2-year mirror-image study.
Nielsen J; Kane JM; Correll CU
Bipolar Disord; 2012 Dec; 14(8):863-9. PubMed ID: 23107278
[TBL] [Abstract][Full Text] [Related]
17. Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics.
Xiu MH; Hui L; Dang YF; Hou TD; Zhang CX; Zheng YL; Chen DC; Kosten TR; Zhang XY
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Nov; 33(8):1508-12. PubMed ID: 19720106
[TBL] [Abstract][Full Text] [Related]
18. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.
Tiihonen J; Haukka J; Taylor M; Haddad PM; Patel MX; Korhonen P
Am J Psychiatry; 2011 Jun; 168(6):603-9. PubMed ID: 21362741
[TBL] [Abstract][Full Text] [Related]
19. [Pharmaco-epidemiological study on antipsychotic drug prescription in French Psychiatry: Patient characteristics, antipsychotic treatment, and care management for schizophrenia].
Brunot A; Lachaux B; Sontag H; Casadebaig F; Philippe A; Rouillon F; Cléry-Melin P; Hergueta T; Llorca PM; Moreaudefarges T; Guillon P; Lebrun T
Encephale; 2002; 28(2):129-38. PubMed ID: 11972139
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E
Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
